In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Virogen Ltd.

www.virogen.com

Latest From Virogen Ltd.

Where Are They Now?

In a new occasional series, START-UP will select companies it profiled in the past to find out what went according to plan, and what didn't. This month, we revisit four anti-infectives discovery companies first profiled in 2000 and draw out some lessons, both from their successes and from their failures, for those starting out today.
BioPharmaceutical

Recent Dealmaking (3/2004)

Summarizing the month in European dealmaking.

Arrow: Focus and Flexibility

In October 2003, infectious diseases start-up Arrow Therapeutics' £21 million funding round from four new international VCs and five existing backers topped the ranks of UK biotech fundraisings. The round shows that investors value a broad pipeline, plus well-connected management able to balance focus with opportunism, more than a product in the clinic or a sexy new technology.
BioPharmaceutical Europe

Perlegen: Will Numbers Enable Pharmacogenomics

Until now, Perlegen contends, pharmacogenomics has failed to deliver because no one has had the statistical power to show connections. With its whole genome scanning technology, Perlegen aims to prove that it can come up with usable and predictive markers of drug response by inexpensively screening for millions of SNPs and analyzing subsequent patterns--even without any significant biological understanding. The start-up aims to use its technology to help compounds win regulatory approval and more market share than they otherwise could. Perlegen also plans to support in-licensed drug candidates and seek disease genes. It wants a share of drug sales its studies enable, and to leverage all the IP it can capture. Absent its own drug discovery and development program, Perlegen needs partners to provide the compounds and clinical samples with which it can create pharmacogenomic data and secure an FDA imprimatur. Competitors argue that smaller sets of data, informed by a clearer biological understanding, will provide equally effective pharmacogenomic data, cheaper.
BioPharmaceutical Strategy
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Infectious & Viral Diseases
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Virogen Ltd.
  • Senior Management
  • Stan Tyms, CEO
    Deborah Taylor, PhD, VP, Research
  • Contact Info
  • Virogen Ltd.
    Phone: (44) 20 8906 3811
    1-3 Burtonhole Ln.
    Mill Hill
    London, NW7 1AD
    UK
UsernamePublicRestriction

Register